DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for hereditary spherocytosis type 4 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHereditary spherocytosis type 4 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hereditary spherocytosis type 4 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
solute carrier family 4 member 1 (Diego blood group) (SLC4A1) — SLC4A1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet clrdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7UZ3 · 2.35 Å · ligand CHOLESTEROL (CLR). Experimental structure, not a prediction.
What the evidence adds up to
A 1978 study of fifteen kindreds with dominant hereditary spherocytosis found significant linkage between the disease and the Gm (IgG) marker, with a maximum lod score of 3.42 at a recombination fraction of 22%. No heterogeneity of the recombination fraction was observed between sexes or between families. The same study provided evidence from a family with an 8/12 translocation that at least one locus for HS is located near the breakpoint of the translocation. The authors concluded these results were compatible with the hypothesis that HS is not a heterogeneous disorder.
A 1981 retrospective study of 50 patients with hereditary spherocytosis from 41 families seen at two Manchester hospitals between 1967 and 1979 found that 19 patients (38%) had no family history of spherocytosis, and in 12 patients (24%), tests on the family showed no evidence of disease. The authors argued that the traditional name "hereditary spherocytosis" is inaccurate in many cases and suggested "congenital spherocytosis" would be more appropriate.
A 1991 review noted that hereditary spherocytosis is a relatively common haematological disorder and that new information on molecular and genetic aspects of pathophysiology was beginning to have implications for its investigation and management. The review stated that these advances had not yet exerted a large influence at the therapeutic level, but held promise for developments such as prenatal diagnosis. A 2011 literature review described hereditary spherocytosis as a common inherited disease presenting with haemolytic anaemia, jaundice and splenomegaly, and discussed contemporary classification and approaches to diagnosis and treatment depending on disease severity.
No drug repurposing data for hereditary spherocytosis type 4 were found in these abstracts. What is missing is any clinical trial testing a repurposed drug for this specific subtype, any molecular stratification of patients beyond linkage analysis, and funding for such trials.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Blood · 1978 · 37 citations · open access
Linkage and gene localization of hereditary spherocytosis (HS)
AbstractFifteen kindreds with dominant hereditary spherocytosis (HS) were studied. Expansion of the data from a family with an 8/12 translocation provided further evidence that at least one locus for HS is located near the breakpoint of the translocation. Linkage analysis of all families showed a lack of linkage with all marker loci studied except for Gm (IgG). Linkage between Gm and HS was shown to be significant with a maximum lod score of 3.42 at a recombination fraction of 22%. No heterogeneity of the recombination fraction was observed either between sexes or between families. These results are compatible with the hypothesis that HS is not a heterogeneous disorder.
Journal of Clinical Pathology · 1991 · 8 citations · open access
Current problems in haematology. 2: Hereditary spherocytosis.
AbstractHereditary spherocytosis is a relatively common haematological disorder and will be encountered by all haematologists. The abundance of new information, dealing principally with molecular and genetic aspects of pathophysiology, is beginning to have implications for its investigation and management. While these advances have not yet exerted a large influence at therapeutic level, the promise of such advents as prenatal diagnosis make this an exciting field to watch.
AbstractA retrospective study of 50 patients with hereditary spherocytosis (HS) from 41 families seen between 1967 and 1979 at the Royal Manchester Children's Hospital, and Booth Hall Children's Hospital, Manchester, England is described. Nineteen patients (38%) had no family history of spherocytosis and in 12 patients (24%), tests on the family showed no evidence of disease. Various modes of inheritance are discussed in the light of these results. The traditional name for the condition (hereditary spherocytosis) is considered unsuitable as it is clearly inaccurate in many cases. The name congenital spherocytosis would be more appropriate.
Health and Ecology Issues · 2011 · 1 citations · open access
HEREDITARY SPHEROCYTOSIS IN CHILDREN: MODERN CONCEPTION (literature review)
AbstractThe modern conception of hereditary spherocytosis has been considered in the article. Hereditary spherocytosis is a common inherited disease declaring itself in haemolytic anaemia, jaundice and splenomegaly. The contemporary classification, approaches to the diagnosis and treatment depending on severity of the disease course and presence of the most frequent complications have been given.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
